DR info

臨床試験数 : 1 / 薬物数 : 10 - (DrugBank : 9) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 73

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Adalimumab
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Certolizumab
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Etanercept
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Golimumab
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Infliximab
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Leflunomide
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Methotrexate
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Pamidronate
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Sulfasalazine
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;
Zoledronic acid
   Seattle Children's Hospital
      2018   -   NCT04725422   United States;